Oncopeptides AB Registered Shs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.05.20	Oncopeptides Reinitiates Patient Enrollment to the Melflufen Clinical Program Following a Temporary Pause due to the COVID-19 Pandemic (PR Newswire)
26.05.20	Bulletin From the Annual General Meeting in Oncopeptides AB (publ) (PR Newswire)
26.05.20	Bulletin From the Annual General Meeting in Oncopeptides AB (publ) (PR Newswire)
26.05.20	Oncopeptides AB: Interim Report Q1 2020 (PR Newswire)
26.05.20	Oncopeptides AB: Interim Report Q1 2020 (PR Newswire)
22.05.20	Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included (PR Newswire)
22.05.20	Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included (PR Newswire)
15.05.20	Oncopeptides Presents Pre-clinical Melflufen Data at the AACR Annual Meeting 2020 That Further Validates the Technical Platform, PDC (PR Newswire)
15.05.20	Oncopeptides Presents Pre-clinical Melflufen Data at the AACR Annual Meeting 2020 That Further Validates the Technical Platform, PDC (PR Newswire)
14.05.20	Oncopeptides Announces New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting (PR Newswire)
14.05.20	Oncopeptides Announces New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting (PR Newswire)
13.05.20	Oncopeptides Announces that Two Abstracts on Multiple Myeloma have been Accepted by the 2020 ASCO Annual Meeting (PR Newswire)
13.05.20	Oncopeptides Announces that Two Abstracts on Multiple Myeloma have been Accepted by the 2020 ASCO Annual Meeting (PR Newswire)
28.04.20	Oncopeptides Annual Report 2019 (PR Newswire)
28.04.20	Oncopeptides Annual Report 2019 (PR Newswire)
22.04.20	Annual General Meeting in Oncopeptides AB (publ) (PR Newswire)
22.04.20	Annual General Meeting in Oncopeptides AB (publ) (PR Newswire)
02.04.20	Oncopeptides Strengthens its Corporate Communications Function by Appointing Rolf Gulliksen as Global Head of Corporate Communications (PR Newswire)
02.04.20	Oncopeptides Strengthens its Corporate Communications Function by Appointing Rolf Gulliksen as Global Head of Corporate Communications (PR Newswire)
26.03.20	Oncopeptides Announces 26% Overall Response Rate of Melflufen in Triple-class Refractory Multiple Myeloma Patients From the Pivotal HORIZON Study (PR Newswire)
26.03.20	Oncopeptides Announces 26% Overall Response Rate of Melflufen in Triple-class Refractory Multiple Myeloma Patients From the Pivotal HORIZON Study (PR Newswire)
24.03.20	The Lancet Haematology Publishes Results From Oncopeptides' Multicenter, International Phase 1/2 Study (O-12-M1) (PR Newswire)
24.03.20	The Lancet Haematology Publishes Results From Oncopeptides' Multicenter, International Phase 1/2 Study (O-12-M1) (PR Newswire)
20.03.20	Oncopeptides Provides Update Regarding COVID-19 Impact on the Melflufen Clinical Program (PR Newswire)
20.03.20	Oncopeptides Provides Update Regarding COVID-19 Impact on the Melflufen Clinical Program (PR Newswire)
02.03.20	Oncopeptides Strengthens its Organization by Appointing Karolina Vilval as General Counsel (PR Newswire)
02.03.20	Oncopeptides Strengthens its Organization by Appointing Karolina Vilval as General Counsel (PR Newswire)
24.01.20	Oncopeptides will Host a Webcast on Monday, January 27th at 11.00 (CET) (PR Newswire)
24.01.20	Oncopeptides will Host a Webcast on Monday, January 27th at 11.00 (CET) (PR Newswire)
07.01.20	Oncopeptides Strengthens its Regulatory Function by Appointing Karin Eklund Vanderpol as Head of Regulatory Affairs (PR Newswire)
07.01.20	Oncopeptides Strengthens its Regulatory Function by Appointing Karin Eklund Vanderpol as Head of Regulatory Affairs (PR Newswire)
17.12.19	Bulletin From the Extraordinary General Meeting in Oncopeptides AB (publ) (PR Newswire)
17.12.19	Bulletin From the Extraordinary General Meeting in Oncopeptides AB (publ) (PR Newswire)
08.12.19	Oncopeptides Presents Promising Data from the Phase 2 ANCHOR Combination Study in Patients With RRMM at ASH Annual Meeting 2019 (PR Newswire)
08.12.19	Oncopeptides Presents Promising Data from the Phase 2 ANCHOR Combination Study in Patients With RRMM at ASH Annual Meeting 2019 (PR Newswire)
07.12.19	Oncopeptides Presents Updated Efficacy and Safety Data from Pivotal Phase 2 HORIZON Study in Patients With RRMM at ASH Annual Meeting 2019 (PR Newswire)
07.12.19	Oncopeptides Presents Updated Efficacy and Safety Data from Pivotal Phase 2 HORIZON Study in Patients With RRMM at ASH Annual Meeting 2019 (PR Newswire)
06.12.19	Oncopeptides Will Host a Webcast on Tuesday, December 10th at 13:00 (CET) to Provide an Update Regarding Data Presented at the ASH Annual Meeting (PR Newswire)
06.12.19	Oncopeptides Will Host a Webcast on Tuesday, December 10th at 13:00 (CET) to Provide an Update Regarding Data Presented at the ASH Annual Meeting (PR Newswire)
02.12.19	Oncopeptides Appoints Joseph Horvat as President North America (PR Newswire)
02.12.19	Oncopeptides Appoints Joseph Horvat as President North America (PR Newswire)
14.11.19	Extraordinary General Meeting in Oncopeptides AB (publ) (PR Newswire)
14.11.19	Extraordinary General Meeting in Oncopeptides AB (publ) (PR Newswire)
06.11.19	Oncopeptides to Highlight Data From Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019 (PR Newswire)
06.11.19	Oncopeptides to Highlight Data From Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019 (PR Newswire)
31.10.19	Number of Shares and Votes in Oncopeptides (PR Newswire)
31.10.19	Number of Shares and Votes in Oncopeptides (PR Newswire)
10.10.19	Nomination Committee Appointed in Respect of AGM 2020 in Oncopeptides (PR Newswire)
10.10.19	Nomination Committee Appointed in Respect of AGM 2020 in Oncopeptides (PR Newswire)
30.09.19	Number of Shares and Votes in Oncopeptides (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Oncopeptides AB Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten